EX1000

Novo Nordisk A/S · Phase 2 active Small molecule

At a glance

Generic name	EX1000
Sponsor	Novo Nordisk A/S
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes (PHASE2)
Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EX1000 CI brief — competitive landscape report
EX1000 updates RSS · CI watch RSS
Novo Nordisk A/S portfolio CI